Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dual antiplatelet therapy effects on NETosis and platelet activation in healthy volunteers
ACTRN12622001427763Phase 2Not yet recruiting
- Sponsor
- Dr. Kathryn Hally
- Start
- Jan 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of aspirin and ticagrelor in coronary arteriosclerosis (2 arms), sponsored by Dr. Kathryn Hally. Primary endpoints: Myeloperoxidase activity in isolated neutrophils with and without platelets, Platelet aggregation by light transmission aggregometry and 1 more. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
aspirinticagrelor
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on ACTRN12622001427763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622001427763.